X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2789) 2789
Publication (453) 453
Book Chapter (51) 51
Book Review (33) 33
Conference Proceeding (12) 12
Dissertation (11) 11
Book / eBook (1) 1
Government Document (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1499) 1499
humans (1421) 1421
parp (977) 977
oncology (888) 888
poly polymerase (883) 883
animals (811) 811
parp inhibitors (739) 739
cancer (708) 708
parp inhibitor (615) 615
poly polymerases - metabolism (565) 565
female (563) 563
apoptosis (555) 555
poly polymerase inhibitors (541) 541
dna repair (506) 506
biochemistry & molecular biology (442) 442
dna damage (438) 438
cell biology (406) 406
cell line, tumor (400) 400
mice (397) 397
homologous recombination (391) 391
ovarian cancer (388) 388
chemotherapy (378) 378
breast cancer (377) 377
male (318) 318
pharmacology & pharmacy (314) 314
mutation (305) 305
tumors (298) 298
article (295) 295
enzyme inhibitors - pharmacology (292) 292
poly polymerase-1 (278) 278
olaparib (274) 274
proteins (247) 247
apoptosis - drug effects (245) 245
monosaccharides (241) 241
sugars (241) 241
dna-damage (239) 239
antineoplastic agents - pharmacology (238) 238
brca1 (235) 235
repair (229) 229
deoxyribonucleic acid--dna (228) 228
expression (222) 222
analysis (219) 219
research (216) 216
synthetic lethality (207) 207
activation (204) 204
cells (197) 197
care and treatment (193) 193
poly polymerase inhibitors - pharmacology (192) 192
inhibitors (188) 188
oxidative stress (178) 178
rats (176) 176
dna (175) 175
dna-repair (172) 172
genetic aspects (171) 171
poly polymerases - genetics (170) 170
ribose (169) 169
chemistry, medicinal (168) 168
antineoplastic agents - therapeutic use (162) 162
poly (160) 160
inhibition (159) 159
neoplasms - drug therapy (154) 154
polymerase (154) 154
health aspects (153) 153
brca2 (152) 152
breast-cancer (152) 152
ovarian neoplasms - drug therapy (150) 150
review (150) 150
cancer therapies (142) 142
cell survival - drug effects (142) 142
poly polymerase inhibitors - therapeutic use (141) 141
gene expression (140) 140
middle aged (139) 139
therapy (138) 138
brca1 protein - genetics (136) 136
cell cycle (135) 135
parp inhibition (135) 135
enzymes (133) 133
cell death (131) 131
aged (130) 130
resistance (128) 128
cell-death (126) 126
dose-response relationship, drug (125) 125
cytotoxicity (123) 123
phthalazines - pharmacology (123) 123
brca (121) 121
cell line (121) 121
medicine & public health (121) 121
breast neoplasms - drug therapy (118) 118
breast neoplasms - genetics (118) 118
in-vitro (118) 118
ovarian-cancer (118) 118
ovarian neoplasms - genetics (117) 117
brca2 protein - genetics (116) 116
adp-ribose polymerase (115) 115
parp-1 (115) 115
cell proliferation - drug effects (113) 113
clinical trials (113) 113
combination (112) 112
phosphorylation (112) 112
piperazines - pharmacology (112) 112
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2770) 2770
French (21) 21
German (16) 16
Polish (6) 6
Czech (5) 5
Chinese (4) 4
Japanese (3) 3
Korean (2) 2
Russian (2) 2
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 2017, Volume 28, Issue 3, pp. 512 - 518
Journal Article
Journal Article
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2015, Volume 137, Issue 3, pp. 386 - 391
Abstract Background Veliparib is a potent small molecule inhibitor of PARP-1/2, which is cytotoxic in tumor cells with deficiencies in BRCA1 or BRCA2 . We... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | BRCA1, BRCA2 mutation | Toxicity | Veliparib | PARP inhibitor | Phase II trial | Ovarian cancer | MULTICENTER | OPEN-LABEL | COMBINATION | PLATINUM-FREE INTERVAL | SOMATIC MUTATIONS | OBSTETRICS & GYNECOLOGY | OLAPARIB | ONCOLOGY | RESISTANCE | HOMOLOGOUS RECOMBINATION | REFRACTORY SOLID TUMORS | POLY(ADP-RIBOSE) POLYMERASE INHIBITOR | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Ovarian Neoplasms - genetics | BRCA1 Protein - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Peritoneal Neoplasms - genetics | Fallopian Tube Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Aged, 80 and over | Carcinoma, Ovarian Epithelial | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Neoplasm Recurrence, Local - genetics | Aged | Genes, BRCA1 | Benzimidazoles - adverse effects | Ovarian Neoplasms - drug therapy | BRCA2 Protein - genetics | Benzimidazoles - therapeutic use | Fallopian Tube Neoplasms - drug therapy | Medical research | Cancer patients | Care and treatment | Gene mutations | Analysis | Medicine, Experimental | Genetic aspects | Cancer | Chemotherapy | Clinical trials | Index Medicus | toxicity | BRCA2 mutation | ovarian cancer | veliparib | BRCA1
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 15, pp. 4066 - 4076
Journal Article
Annals of Oncology, ISSN 0923-7534, 04/2016, Volume 27, Issue suppl 1, pp. i40 - i44
Slow progress in improving the outcome of ovarian cancer with chemotherapy over the last decade has stimulated research into molecularly targeted therapy.... 
Olaparib | Maintenance therapy | Homologous recombination deficiency | PARP inhibitors | BRCA mutation | Ovarian cancer | Drug Synergism | Humans | Female | Mutation | Drug Discovery | Ovarian Neoplasms - drug therapy | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 06/2018, Volume 149, Issue 3, pp. 575 - 584
Homologous recombination (HR)-proficient ovarian tumors have poorer clinical outcomes and show resistance to poly ADP ribose polymerase inhibitors (PARPi). A... 
BET inhibitor | Homologous recombination | PARP inhibitor | Ovarian cancer | DNA-DAMAGE | BRCA1 | OBSTETRICS & GYNECOLOGY | REPAIR | GENE | ONCOLOGY | GROWTH | BROMODOMAIN INHIBITION | CELL-CYCLE | CARCINOMA | REVEALS | BRD4 | Piperazines - administration & dosage | Homologous Recombination - drug effects | Humans | Neoplasms, Glandular and Epithelial - metabolism | Indoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | BRCA1 Protein - metabolism | Organic Chemicals - pharmacology | Female | Indoles - pharmacology | Ovarian Neoplasms - metabolism | Nuclear Proteins - genetics | Ovarian Neoplasms - drug therapy | Phthalazines - administration & dosage | Organic Chemicals - therapeutic use | Nuclear Proteins - metabolism | Transcription Factors - antagonists & inhibitors | Transcription Factors - genetics | Down-Regulation - drug effects | Mice, SCID | Piperazines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Drug Synergism | Transcription Factors - metabolism | Xenograft Model Antitumor Assays | BRCA1 Protein - genetics | Phthalazines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Animals | Mice, Nude | Nuclear Proteins - antagonists & inhibitors | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Cell Line, Tumor | Mice, Inbred NOD | Mice | Prevention | Biotechnology | Sugars | Cancer | Monosaccharides | homologous recombination | ovarian cancer
Journal Article
Journal Article